Cerenis Therapeutics (France), a clinical-stage biopharmaceutical company focused on the regression of atherosclerotic plaque and the enhancement of HDL function, closed a $40M Series C financing. Participants include Fund for Strategic Investment, Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.

InVasc Therapeutics (Tucker, GA) a clinical-stage biopharmaceutical company focused on the cardiometabloic diseases chronic kidney disease and atherosclerosis, closed a $3.1M Series A financing. Participants include Trois I Investments Industriels Internationaux.

Relypsa (Santa Clara, CA) a clinical-stage developer of a therapeutic for hyperkalemia in congestive heart failure patients, closed a $70M Series B financing. Participants include 5AM Ventures, New Leaf Partners, Delphi Ventures and OrbiMed Advisors.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on end stage renal disease, congestive heart failure, chronic kidney disease, and hypertension, closed a $21M Series B financing. Participants include AgeChem, CMEA Capital, ARCH Venture Partners, Sofinnova Ventures and Dow Venture Capital.

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

NormOxys (Wellesley, MA) a clinical-stage small molecule company focused on allosteric effectors of hemoglobin for heart failure and various cancers, closed a $17.5M Series B financing. Participants include Care Capital and Index Ventures.

Cellular Dynamics (Madison, WA) a commercial-stage supplier of cardiomyocytes derived from, closed a $40.6M Series B financing. Participants include Tactics II Stem Cell Ventures, Equity Group Investments and Sixth Floor Investors.

Omthera Pharmaceuticals (Bedminster, NJ) a clinical-stage specialty biopharma company focused on an Omega-3 fatty acid containing DHA and EPA as a therapy for dyslipidemia, closed a $6.5M Series A financing. Participants include Sofinnova Partners.

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Xigen (Switzerland) a clinical-stage biopharma company focused on Jun Kinase inhibitor for stroke, inflammation and hearing loss, closed a $20M Series B financing. Participants have included Tilocor Life Sciences, VI Partners and DEFI Gestion.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $27,5M Series B financing. Participants include Wellington Partners Venture Capital, Aravis Venture Associates, Auriga Partners and Vinci Capital.